Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases


Oruc Z., Kaplan M. A. , KARAAĞAÇ M., Ozyurt N., TATLI A. M. , Kaya A. O. , ...More

FUTURE ONCOLOGY, vol.17, pp.1611-1624, 2021 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 17
  • Publication Date: 2021
  • Doi Number: 10.2217/fon-2020-1032
  • Title of Journal : FUTURE ONCOLOGY
  • Page Numbers: pp.1611-1624

Abstract

Aim: To assess the efficacy and tolerability of the first-line treatment options for hormone-refractory prostate cancer patients with visceral metastases. Materials and methods: The records of 191 patients diagnosed with hormone-refractory prostate cancer with visceral metastases were analyzed retrospectively. Results: Docetaxel was administered to 61.2% (n = 117), abiraterone to 14.2% (n = 27) and enzalutamide to 9.4% (n = 18) as the first-line treatment. The median survival of the patients receiving docetaxel, abiraterone and enzalutamide as the first-line treatment during the hormone-refractory period was 15 (95% Cl: 12.9-17) months, 6 (95% Cl: 1.8-10.1) months and 11 (95% Cl: 0.9-23.1) months (p = 0.038), respectively. Conclusion: The present study established a statistically significant difference in favor of docetaxel in terms of overall survival and progression-free survival.